You are here

Contrave

Orexigen’s Weight-Loss Roller Coaster to End With a Bankruptcy Sale

Orexigen’s Weight-Loss Roller Coaster to End With a Bankruptcy Sale

Xconomy

Flag link:

Troubled Orexigen looks for a buyer, but will anyone want Contrave?

Troubled Orexigen looks for a buyer, but will anyone want Contrave?

Fierce Pharma

Orexigen Therapeutics

Flag link:

Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns

Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns

Endpoints

Flag link:

The FDA cites risk info in letter over Contrave DTC ad

The FDA cites risk info in letter over Contrave DTC ad

Medical Marketing and Media

Orexigen Therapeutics

Flag link:

Orexigen - Contrave Sales Present Troubling Data

Orexigen - Contrave Sales Present Troubling Data

Seeking Alpha

Flag link:

Orexigen struggles to stay afloat as obesity market stagnates

Orexigen struggles to stay afloat as obesity market stagnates

BioPharma Dive

Flag link:

Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial

Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial

Seeking Alpha

Flag link:

Orexigen: Contrave Sales Flatten Out At End Of Q1

Orexigen: Contrave Sales Flatten Out At End Of Q1

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant

Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant

Yahoo/Reuters

Valeant Pharmaceuticals

Flag link:

Orexigen takes another body blow from ill-fated Contrave trial

Orexigen takes another body blow from ill-fated Contrave trial

Fierce Pharma

clinical trials

Flag link:

Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says

Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says

Fierce Pharma Marketing

Flag link:

Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says

Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says

Fierce Pharma Marketing

Flag link:

Contrave script growth snags, despite Takeda's 900-strong salesforce

Contrave script growth snags, despite Takeda's 900-strong salesforce

Fierce Pharma Marketing

Flag link:

Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?

Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?

Motley Fool

Flag link:

Here's What Caused Orexigen Therapeutics to Slim Down in August

Here's What Caused Orexigen Therapeutics to Slim Down in August

Motley Fool

Orexigen Therapeutics

Flag link:

Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed

Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap

Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap

Fierce Pharma Marketing

Arena Pharmaceuticals

Flag link:

Orexigen, Takeda take Actavis to court over obesity med Contrave generic

Orexigen, Takeda take Actavis to court over obesity med Contrave generic

BioPharma Dive

Flag link:

Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents

Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents

Yahoo

Flag link:

Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate

Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Pages